V160

human cytomegalovirus vaccine V160 · Merck Sharp & Dohme LLC

Drug timelines are a Plus or Pro feature.

3 regulatory and trial events tracked for V160, covering 2021-11-01 to 2021-11-15. Get the full timeline:

Most recent: Clinical Trial Update: Safety and Immunogenicity of the Human Cytomegalovirus (CMV) Vaccine (V160) in Healthy Japanese Men (V160-003) [Phase 1]

See pricing